Health Catalyst Inc
$ 1.73
-25.11%
07 Aug - close price
- Market Cap 170,695,000 USD
- Current Price $ 1.73
- High / Low $ 1.87 / 1.66
- Stock P/E N/A
- Book Value 1.87
- EPS -3.62
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.03 %
- ROE -1.03 %
- 52 Week High 3.80
- 52 Week Low 0.96
About
Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations. The company is headquartered in South Jordan, Utah.
Analyst Target Price
$2.31
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-06 | 2026-05-11 | 2026-03-12 | 2025-11-10 | 2025-08-07 | 2025-05-07 | 2025-02-26 | 2024-11-06 | 2024-08-07 | 2024-05-09 | 2024-02-22 | 2023-11-02 |
| Reported EPS | -0.08 | 0.02 | 0.08 | 0.06 | -0.08 | 0.01 | 0.04 | 0.07 | 0.12 | 0.05 | 0.02 | 0.03 |
| Estimated EPS | -0.05 | 0.01 | 0.0954 | 0.07 | -0.09 | 0.03 | 0.0764 | 0.09 | 0.08 | 0.03 | -0.01 | -0.01 |
| Surprise | -0.03 | 0.01 | -0.0154 | -0.01 | 0.01 | -0.02 | -0.0364 | -0.02 | 0.04 | 0.02 | 0.03 | 0.04 |
| Surprise Percentage | -60% | 100% | -16.1426% | -14.2857% | 11.1111% | -66.6667% | -47.644% | -22.2222% | 50% | 66.6667% | 300% | 400% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: HCAT
2026-08-07 04:12:07
Health Catalyst, Inc. (NASDAQ: HCAT) reported a net loss of $151.6 million for the first half of 2026, primarily due to a $122.5 million goodwill impairment charge. The company also announced the sale of its Vitalware business to Med-Metrix for $147 million, with the proceeds used to repay outstanding debt. Revenue declined year-over-year, impacting profitability, though operating cash flow improved.
2026-08-06 23:12:07
Health Catalyst (HCAT) reported Q2 2026 revenue above Wall Street expectations, reaching $70.5 million, and adjusted EBITDA at the high end of guidance. However, the company's shares sank by over 27% in after-hours trading due to a weaker full-year outlook, which was primarily impacted by the divestiture of Vitalware and ongoing platform migration costs. Management emphasized a strategic shift towards core technology opportunities, debt elimination, and a multi-year transformation, prioritizing long-term value over short-term results.
2026-08-06 21:12:07
Health Catalyst, a healthcare intelligence company, has completed the sale of its mid-revenue cycle business, Vitalware, to Med-Metrix for $147 million. This divestiture allows Health Catalyst to repay its credit facility, eliminating approximately $19 million in annual interest expense, and focus its capital and operational efforts on scaling its core healthcare intelligence platform and AI-driven decisioning tools. The company aims to leverage its 18 years of proprietary analytics and $2.8 billion in documented clinical and financial outcomes to drive sustainable operational change for health systems.
2026-08-06 21:00:07
HEALTH CATALYST ($HCAT) announced its Q2 2026 earnings, reporting $0.04 per share, beating estimates by $0.01, and revenue of $70.49 million, surpassing estimates. Despite strong earnings, the stock price decreased by 27.83% since market close. The article also details recent hedge fund activity in HCAT stock and analyst price targets.
2026-08-06 20:12:07
Health Catalyst announced the completion of the sale of its Vitalware business to Med-Metrix, LLC, on July 31, 2026, for $147 million. The company used the proceeds to repay its credit facility debt, eliminating approximately $19 million in annual interest expense. This divestiture allows Health Catalyst to sharpen its focus on its core healthcare intelligence strategy, leveraging its 18 years of proprietary data and AI-driven products to help health systems improve performance across cost, clinical quality, and consumer loyalty.
2026-08-06 20:12:07
Health Catalyst (Nasdaq: HCAT) reported its financial results for the second quarter ended June 30, 2026, exceeding revenue guidance and adjusting EBITDA. The company's CEO, Ben Albert, highlighted the Vitalware divestiture and debt repayment as significant balance sheet improvements. Health Catalyst also provided its financial outlook for the third quarter and full year 2026, expecting total revenue of $55 million to $56 million for Q3 and $246 million to $249 million for the full year.
